Page 79 - Haematologica June

Effects of HC and IFN-α on PV RBC adhesion
inhibition of Lu/BCAM protein phosphory-
lation. Blood. 2010;116(12):2152-2159.
24. Gauthier E, Rahuel C, Wautier MP, et al. Protein kinase A-dependent phosphoryla- tion of Lutheran/basal cell adhesion mole- cule glycoprotein regulates cell adhesion to laminin alpha5. J Biol Chem.
2005;280(34):30055-30062.
25. El Nemer W, Gane P, Colin Y, et al. The
Lutheran blood group glycoproteins, the erythroid receptors for laminin, are adhe- sion molecules. J Biol Chem. 1998; 273(27):16686-16693.
26. De Grandis M, Cassinat B, Kiladjian JJ, Chomienne C, El Nemer W. Lu/BCAM- mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients. Am J Hematol. 2015;90(7):E137-138.
27. Antonioli E, Carobbio A, Pieri L, et al. Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombo- cythemia. Haematologica. 2010;95(8):1435- 1438.
28. Bogdanova A, Makhro A, Wang J, Lipp P, Kaestner L. Calcium in red blood cells-a perilous balance. Int J Mol Sci. 2013; 14(5):9848-9872.
29. Charache S. Fetal hemoglobin, sickling, and sickle cell disease. Adv Pediatr. 1990;37:1-31.
30. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest.
1984;74(2):652-656.
31. Odievre MH, Bony V, Benkerrou M, et al.
Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease. Haematologica. 2008;93(4):502-510.
32. Chaar V, Laurance S, Lapoumeroulie C, et al. Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endotheli- um by inhibiting endothelial lutheran/basal cell adhesion molecule (Lu/BCAM) through phosphodiesterase 4A activation. J Biol Chem. 2014;289(16):11512-11521.
33. Glover RE, Ivy ED, Orringer EP, Maeda H, Mason RP. Detection of nitrosyl hemoglo- bin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Mol Pharmacol. 1999;55(6):1006-1010.
34. Jiang J, Jordan SJ, Barr DP, Gunther MR, Maeda H, Mason RP. In vivo production of nitric oxide in rats after administration of hydroxyurea. Mol Pharmacol. 1997;52(6):1081-1086.
35. Nahavandi M, Wyche MQ, Perlin E, Tavakkoli F, Castro O. Nitric Oxide Metabolites in Sickle Cell Anemia Patients after Oral Administration of Hydroxyurea;
Hemoglobinopathy. Hematology. 2000;
5(4):335-339.
36. Kleinbongard P, Schulz R, Rassaf T, et al.
Red blood cells express a functional endothelial nitric oxide synthase. Blood. 2006;107(7):2943-2951.
37. Kawasaki K, Smith RS Jr, Hsieh CM, Sun J, Chao J, Liao JK. Activation of the phos- phatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol. 2003;23(16):5726-5737.
38. Mejia-Garcia TA, Portugal CC, Encarnacao TG, Prado MA, Paes-de-Carvalho R. Nitric oxide regulates AKT phosphorylation and nuclear translocation in cultured retinal cells. Cell Signal. 2013;25(12):2424-2439.
39. Cokic VP, Andric SA, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood. 2008;111(3):1117-1123.
40. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96(13):4261-4266.
41. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33(5):523-530.
42. Cerletti C, Tamburrelli C, Izzi B, Gianfagna F, de Gaetano G. Platelet-leukocyte interac- tions in thrombosis. Thromb Res. 2012;129(3):263-266.
43. Papayannopoulou T, Brice M. Integrin expression profiles during erythroid differ- entiation. Blood. 1992;79(7):1686-1694.
44. Spring FA, Holmes CH, Simpson KL, et al. The Oka blood group antigen is a marker for the M6 leukocyte activation antigen, the human homolog of OX-47 antigen, basigin and neurothelin, an immunoglobu- lin superfamily molecule that is widely expressed in human cells and tissues. Eur J Immunol. 1997;27(4):891-897.
45. Coste I, Gauchat JF, Wilson A, et al. Unavailability of CD147 leads to selective erythrocyte trapping in the spleen. Blood. 2001;97(12):3984-3988.
46. Mutin M, Dignat-George F, Sampol J. Immunologic phenotype of cultured endothelial cells: quantitative analysis of cell surface molecules. Tissue Antigens. 1997;50(5):449-458.
47. Crosnier C, Bustamante LY, Bartholdson SJ, et al. Basigin is a receptor essential for ery- throcyte invasion by Plasmodium falci- parum. Nature. 2011;480(7378):534-537.
48. Bernemann TM, Podda M, Wolter M, Boehncke WH. Expression of the basal cell
adhesion molecule (B-CAM) in normal and diseased human skin. J Cutan Pathol. 2000;27(3):108-111.
49. Garinchesa P, Sanzmoncasi M, Campbell I, Rettig W. Non-polarized expression of Basal-cell adhesion molecule B-cam in epithelial ovarian cancers. Int J Oncol. 1994;5(6):1261-1266.
50. Rettig WJ, Garin-Chesa P, Beresford HR, Oettgen HF, Melamed MR, Old LJ. Cell-sur- face glycoproteins of human sarcomas: dif- ferential expression in normal and malig- nant tissues and cultured cells. Proc Natl Acad Sci USA. 1988;85(9):3110-3114.
51. Schon M, Klein CE, Hogenkamp V, Kaufmann R, Wienrich BG, Schon MP. Basal-cell adhesion molecule (B-CAM) is induced in epithelial skin tumors and inflammatory epidermis, and is expressed at cell-cell and cell-substrate contact sites. J Invest Dermatol. 2000;115(6):1047-1053.
52. Xiong L, Edwards CK 3rd, Zhou L. The bio- logical function and clinical utilization of CD147 in human diseases: a review of the current scientific literature. Int J Mol Sci. 2014;15(10):17411-17441.
53. Yang JM, O'Neill P, Jin W, et al. Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to Anoikis through inhibition of Bim. J Biol Chem. 2006;281(14):9719-9727.
54. Chen Y, Zhang H, Gou X, Horikawa Y, Xing J, Chen Z. Upregulation of HAb18G/CD147 in activated human umbilical vein endothelial cells enhances the angiogenesis. Cancer Lett. 2009;278(1):113-121.
55. Dai JY, Dou KF, Wang CH, et al. The inter- action of HAb18G/CD147 with integrin alpha6beta1 and its implications for the invasion potential of human hepatoma cells. BMC Cancer. 2009;9:337.
56. Le Floch R, Chiche J, Marchiq I, et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of gly- colytic tumors. Proc Natl Acad Sci USA. 2011;108(40):16663-16668.
57. Najean Y, Rain JD. Treatment of poly- cythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90(9):3370-3377.
58. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997;34(1):17-23.
59. Silver RT. Long-term effects of the treat- ment of polycythemia vera with recombi- nant interferon-alpha. Cancer. 2006; 107(3):451-458.
haematologica | 2018; 103(6)
981